Myelodysplastic syndrome associated with isolated del(5q)

Name
Myelodysplastic syndrome associated with isolated del(5q)
ICD-O-3 Morphology
9986/3
Effective 2001 and later
Reportable
for cases diagnosed 2001 and later
Primary Site(s)
C421
Primary site must be bone marrow (C421)

Help me code for diagnosis year :

Grade
9 - Grade/differentiation unknown, not stated, or not applicable
Module Rule
None
Alternate Names
5q- syndrome
MDS with 5q deletion
Myelodysplastic syndrome with 5q deletion (5q-syndrome)
Definition
Bone marrow dysplasia showing refractory macrocytic anemia with oval macrocytes and nonlobulated megakaryocytes. 75% of patients have increased cellularity of marrow. One third of patients have chromosomal abnormality that consists of deletion of the long arm of chromosome 5 (5q). Marrow blasts <5%.
Platelet count normal to elevated
No Auer rods
Normal to increased megakaryocytes
Abstractor Notes
MDS with associated del(5q) is an MDS involves that blood and bone marrow.

For MDS diseases (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992), abstracting each of the subtypes would result in over-counting of the diseases.
1. Code only the first subtype that is diagnosed.
2. Do not change the histology code or create a new abstract for any subsequent specific MDS subtypes

Recently the thalidomide analog lenalidomide has been shown to benefit MDS patients. Transfusion independence was achieved in two-thirds of patients.
Definitive Diagnostic Methods
Bone marrow biopsy
Genetic testing
Genetics Data
Deletion between bands q31 and q33 on chromosome 5
Immunophenotyping
None
Treatments
Bone marrow transplant
Chemotherapy
Immunotherapy
Stem cell transplant
Transformations from
None
Corresponding ICD-9 Codes
238.74 Myelodysplastic syndrome with 5q deletion
Corresponding ICD-10 Codes
D46.7 Other myelodysplastic syndromes
Corresponding ICD-10-CM Codes (effective October 1, 2015 U.S. only)
D46.C Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
Signs and Symptoms
Easy bruising or bleeding
Petechiae (flat, pinpoint spots under the skin caused by bleeding)
Shortness of breath
Skin paler than usual
Weakness or feeling tired
Progression and Transformation
<10% of cases transform to AML
Epidemiology and Mortality
Age: 67 years median age
Sex: female predominance
Survival: 145 month median survival